These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29796708)

  • 1. Should palonosetron be a preferred 5-HT
    Chow R; Warr DG; Navari RM; Tsao M; Popovic M; Chiu L; Milakovic M; Lam H; DeAngelis C
    Support Care Cancer; 2018 Aug; 26(8):2519-2549. PubMed ID: 29796708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
    Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
    Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis.
    Yamaguchi A; Saito Y; Takekuma Y; Sugawara M
    Support Care Cancer; 2023 Dec; 32(1):58. PubMed ID: 38145979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting.
    Yang Y; Zhang L
    Chin Clin Oncol; 2020 Apr; 9(2):17. PubMed ID: 31865713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
    Hsu YC; Chen CY; Tam KW; Hsu CY
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1597-1609. PubMed ID: 33993343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis.
    Chow R; Aapro M; Navari RM; Gralla R; Chiu N; Chiu L; Chan S; Popovic M; Lam H; Lock M; DeAngelis C
    Crit Rev Oncol Hematol; 2019 Oct; 142():164-186. PubMed ID: 31419719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Opin Pharmacother; 2014 Dec; 15(17):2599-608. PubMed ID: 25323946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
    Popovic M; Warr DG; Deangelis C; Tsao M; Chan KK; Poon M; Yip C; Pulenzas N; Lam H; Zhang L; Chow E
    Support Care Cancer; 2014 Jun; 22(6):1685-97. PubMed ID: 24590374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
    Likun Z; Xiang J; Yi B; Xin D; Tao ZL
    Oncologist; 2011; 16(2):207-16. PubMed ID: 21282670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
    dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
    J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
    Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
    J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
    Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
    Okada Y; Oba K; Furukawa N; Kosaka Y; Okita K; Yuki S; Komatsu Y; Celio L; Aapro M
    Oncologist; 2019 Dec; 24(12):1593-1600. PubMed ID: 31217343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
    Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.
    Tricco AC; Blondal E; Veroniki AA; Soobiah C; Vafaei A; Ivory J; Strifler L; Cardoso R; Reynen E; Nincic V; Ashoor H; Ho J; Ng C; Johnson C; Lillie E; Antony J; Roberts DJ; Hemmelgarn BR; Straus SE
    BMC Med; 2016 Dec; 14(1):216. PubMed ID: 28007031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
    Fabi A; Malaguti P
    Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials.
    van der Vorst MJ; Neefjes EC; Konings IR; Verheul HM
    Support Care Cancer; 2015 Aug; 23(8):2499-506. PubMed ID: 26041480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.